12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Egrifta tesamorelin regulatory update

Theratechnologies announced that Health Canada agreed to resume review of an NDS for Egrifta tesamorelin to treat excess abdominal fat in HIV-infected patients with lipodystrophy. In March, the application received a notice of non-compliance-withdrawal (NON/w), which concluded the risks of tesamorelin...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >